Search for a trial

A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis

This study has been transitioned to CTIS with ID 2024-513075-40-00 check the CTIS register for the current data. To evaluate the efficacy of blmf in patients with relapsed or refractory AL amyloidosis.

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors

This study has been transitioned to CTIS with ID 2023-503905-12-00 check the CTIS register for the current data. The main objectives for this study are: - To assess the safety and tolerability of the combination of pembrolizumab and lenvatinib and…

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH MELANOMA (MORPHEUS-MELANOMA)

• To evaluate the efficacy of treatment• To evaluate the safety of treatment

A Phase 2, Randomized, Double-blind, Placebo-controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Primary objectives:Cohort 1 and 21. To evaluate the safety and tolerability of multiple doses of belcesiran in patients with AATLD2. To characterize the pharmacodynamics of belcesiran in patients with AATLDCohort 3 1. To characterize the…

THE IMPACT OF PSILOCYBIN ON PAIN IN FIBROMYALGIA PATIENTS:
A MULTICENTER TRIAL

This study has been transitioned to CTIS with ID 2024-516890-63-00 check the CTIS register for the current data. Primary Objective: The primary objective is to assess the effects of low psilocybin doses on pain perception in FM patients and their…

A PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF GLOFITAMAB IN COMBINATION WITH RITUXIMAB (R) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN CIRCULATING TUMOR (ct)DNA HIGH-RISK PATIENTS WITH UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA

This study has been transitioned to CTIS with ID 2023-504994-19-00 check the CTIS register for the current data. This Phase II, open-label, multicenter study, will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with…

A Phase 2 Randomized Study of Relatlimab plus Nivolumab in
Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

This study has been transitioned to CTIS with ID 2023-508372-10-00 check the CTIS register for the current data. Part 1: dose safety confirmationPrimary: To evaluate the proportion of participants with TRAEs leading to discontinuation within 12…

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

This study has been transitioned to CTIS with ID 2024-516728-32-00 check the CTIS register for the current data. To determine RD of elenestinibTo assess if treatment with elenestinib improves outcomes compared to placebo + BSC, as assessed using the…

A Phase I/II, Single-Arm, Open-label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged >= 1 to < 7 Years with Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE)

Primary objectives:- To determine the PK of selumetinib after administration of the selumetinib granule formulation. - To assess the safety and tolerability of the selumetinib granule formulation.

A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT)M erkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve

Primary Objectives- Cohort 1 Part 1: To determine the KRT-232 recommended phase 2 dose (RP2D)- Cohort 1 Part 2: To determine the objective response rate (ORR) in subjects with p53WT MCC who have failed anti-PD-1 or anti-PD-L1 immunotherapy- Cohort 2…

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

This study has been transitioned to CTIS with ID 2024-513759-34-00 check the CTIS register for the current data. Primary ObjectivesPhase 2The primary objectives of Phase 2 are:• To evaluate short- and long-term safety and tolerability of SNDX 5613…

Cemiplimab treatment in patients with locally advanced and metastatic secondary angiosarcomas

Primary objective: 1) To evaluate the overall response rate (ORR) after 24 weeks of cemiplimab in secondary angiosarcomas, according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 or daylight photography as per WHO Offset Publication…

A phase 2, double blind, randomized, placebo controlled clinical trial to investigate the safety and effects of oral vitamin K2 supplementation in COVID-19.

Primary objectives: - To evaluate the effect of oral vitamin K2 supplementation on extrahepatic vitamin K status, as measured by circulating dp-ucMGP, during COVID-19 requiring hospital admission- To evaluate the effect of oral vitamin K2…

Interaction between intestine and osteoarthritis of the hand and the effect of Sustained Release Calcium Butyrate

This proof of concept study is to estimate the effect of SRCaBu (600 mg daily for four weeks) on compositional and functional characteristics of the microbiome for future sample size calculation.The secondary objectives: 1) To evaluate the short-…

Feasibility of a 13-week resistance exercise and protein supplementation intervention in sarcopenic geriatric rehabilitation inpatients: EMPOWER-GR

The objective of the study is to investigate the feasibility of a combined resistance exercise training (RET) and protein supplementation (ONS) intervention and explore the effect on muscle mass and other parameters compared to standard of care in…

TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL

This study will evaluate the efficacy and safety of multiple therapies that are selected using somatic alterations and potential predictive biomarkers identified via NGS assays in patients with solid tumors:

IMPROVING OUTCOME IN SUBARACHNOID HEMORRHAGE WITH NADROPARINE

This study has been transitioned to CTIS with ID 2024-511679-14-00 check the CTIS register for the current data. Our primary objective is to evaluate whether aSAH patients treated with therapeutic dose nadroparine have a lower 30-days mortality rate…

Effect of intranasal administration of palivizumab on experimental respiratory syncytial viral infection * a human challenge study

Study A: Validation of productive infection of RSV CHIM Study B: Effectiveness and immunogenicity of local administration of palivizumab on prevention of experimental RSV infection

Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability,
and Efficacy of EDIT-101 in Adult and Pediatric Participants with Leber Congenital Amaurosis
Type 10 (LCA10), with Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration
Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in
Intron 26 (IVS26) of the CEP290 Gene (*LCA10-IVS26*)

Primary-To evaluate the safety and tolerability of a single dose of EDIT-101 when administered to participants with LCA10-IVS26 mutationSecondary-To evaluate different doses of EDIT-101 for subsequent clinical evaluation-To evaluate the efficacy of…

Leflunomide and Hydroxychloroquine combination therapy
for primary Sjögren*s Syndrome

This study has been transitioned to CTIS with ID 2024-510904-36-00 check the CTIS register for the current data. To assess clinical efficacy and safety of Leflunomide/Hydroxychloroquine in pSS patients in a phase IIb placebo-controlled randomized…